SCG Cell Therapy gets China thumbs-up for study of potentially curative HBV treatmentnews2025-07-08T11:17:10+00:00July 8th, 2025|Endpoints News|
US investors divided on China’s biotech risenews2025-07-02T15:00:45+00:00July 2nd, 2025|Endpoints News|
Innovent brings a new mechanism to obesity market with China approvalnews2025-06-27T14:28:44+00:00June 27th, 2025|Endpoints News|
BIO’s new chair on FDA changes, most favored nation pricing and Chinanews2025-06-18T16:19:09+00:00June 18th, 2025|Endpoints News|
Endpoints Livestream: China is still the top conversation starter at BIOnews2025-06-18T12:51:31+00:00June 18th, 2025|Endpoints News|
NextCure inks ADC deal with Simcere Zaimingnews2025-06-16T14:09:21+00:00June 16th, 2025|Endpoints News|
AstraZeneca, CSPC ink AI drug development deal for $110M upfront news2025-06-13T10:58:25+00:00June 13th, 2025|Endpoints News|
China is closing in on US biotech, Harvard report warnsnews2025-06-05T19:09:12+00:00June 5th, 2025|Endpoints News|
Sagimet touts China partner Ascletis’ Phase 3 FASN inhibitor data in acnenews2025-06-04T15:44:00+00:00June 4th, 2025|Endpoints News|
Regeneron makes $80M obesity deal with Hansohnews2025-06-02T15:11:14+00:00June 2nd, 2025|Endpoints News|
